Clinician's Guide to Spinal Muscular Atrophy

Jump to:
Medical advisors icon

Meet our

Medical advisors

Edward Smith, M.D.

Edward Smith, MD

Melissa Wright, MD, PhD

SMA Classification and Typing

Written by Margaret Anne Rockwood | Last updated July 6th, 2026
✅ Medically reviewed by Edward Smith, MD

 

Once spinal muscular atrophy (SMA) has been genetically confirmed, the next step is determining the disease type.

All major forms of SMA are caused by abnormalities in the SMN1 gene, however, patients can experience dramatically different degrees of weakness and disability. Typing helps predict disease severity and guide treatment decision-making.

Factors Used to Determine SMA Type

Historically, SMA types were defined according to age of onset and the highest motor milestone achieved. Today, guidelines recommend considering SMN2 copy number because it often correlates with disease severity.

However, SMN2 copy number is not the only factor. Clinical presentation remains the most important determinant of SMA type because it reflects the patient’s actual functional abilities and disease severity, whereas SMN2 copy number is an imperfect predictor of phenotype. This distinction has become even more important as early treatment can alter the disease’s course and enable some patients to achieve developmental milestones that would not have been predicted by SMN2 copy number alone.

Once SMA has been diagnosed, physicians classify disease severity using several factors:

  • age at symptom onset
  • highest motor milestone achieved
  • degree of weakness and respiratory involvement
  • SMN2 copy number
  • overall clinical course

Although higher SMN2 copy numbers generally predict milder disease, significant overlap exists between categories. For this reason, SMA type is ultimately assigned based on clinical presentation rather than genetic testing alone.

 

Traditional SMA Classification

Scroll horizontally to view all columns -->

SMA Type Typical Age of Onset Clinical Features Highest Motor Milestone
Type 0 Prenatal or at birth Severe fetal weakness, decreased fetal movement, profound hypotonia respiratory failure at birth Never achieve head control or independent sitting
Type 1 (Werdnig-Hoffmann) Before 6 months Severe hypotonia, feeding difficulties, respiratory weakness Never sit independently
Type 2 6–18 months Intermediate weakness, scoliosis, contractures Sit independently but never walk independently
Type 3 (Kugelberg-Welander) After 18 months through adolescence Progressive proximal weakness and gait impairment Achieve independent walking
Type 4 Adult-onset, typically after age 21 Mild proximal weakness with slow progression Maintain independent ambulation

The Role of SMN2 Copy Number

SMN2 copy number is the most important genetic predictor of disease severity.

Scroll horizontally to view all columns -->

SMA Type Typical SMN2 Copy Number
Type 0 Most commonly, 1 copy
Type 1 Usually 2 copies
Type 2 Usually 3 copies
Type 3 Usually 3 to 4 copies
Type 4 Typically 4 or more copies

These associations are helpful but not absolute. Although SMN2 copy number is the strongest genetic modifier of disease severity, other genetic and environmental factors also contribute to phenotypic variability.

Additional Evaluations by Type

Once an SMA type has been assigned, additional evaluations help characterize disease severity, establish a functional baseline, and monitor disease progression. The specific assessments performed often vary according to the patient’s age, symptoms, degree of disability, and response to disease-modifying therapies.

SMA Type 1

Infants with SMA Type 1 typically require close monitoring of respiratory and bulbar function because these systems are often affected early in the disease course. Common evaluations include:

  • A pulmonary assessment to identify respiratory muscle weakness
  • swallow studies to evaluate aspiration risk and feeding safety
  • A nutritional assessment and growth monitoring
  • functional motor scales to document developmental progress

SMA Type 2

Children with SMA Type 2 are at increased risk for scoliosis, contractures, and progressive respiratory impairment. Monitoring commonly includes:

  • pulmonary function testing
  • periodic spinal imaging to evaluate scoliosis
  • nutritional and swallowing assessments
  • functional motor scales to track disease progression and treatment response

SMA Type 3

Patients with SMA Type 3 (typical onset is 18 months to 18 years) generally remain ambulatory for many years but may experience progressive gait impairment and loss of endurance. Evaluations often focus on mobility and function, including:

  • gait analysis
  • functional motor assessments
  • orthopedic evaluation for developing contractures or scoliosis
  • pulmonary testing when clinically indicated

SMA Type 4

Adult-onset SMA, or Type 4, typically involves individuals who experience slowly progressive proximal weakness with minimal respiratory involvement. Evaluations should be individualized and may include:

  • functional strength and mobility assessments
  • electromyography (EMG) when diagnostic uncertainty exists
  • muscle MRI in selected cases
  • pulmonary testing if symptoms suggest respiratory involvement

Because adult-onset weakness can result from many neuromuscular disorders, physicians often perform a broader neuromuscular evaluation while investigating adult-onset weakness to differentiate from amyotrophic lateral sclerosis, myopathies, and peripheral neuropathies that may have similar symptoms to Type 4 SMA.

When Classification Is Uncertain

Not every patient fits neatly into a traditional category. Early treatment with modern disease-modifying therapies has blurred historical distinctions because many treated children achieve developmental milestones that would not have been expected in the natural history of the disease.

As a result, the medical field is increasingly viewing SMA as a spectrum disorder rather than a collection of rigid categories. Nevertheless, the traditional classification system remains useful for describing disease severity and functional abilities. SMA type continues to play an important role in prognosis, clinical monitoring, and communication among healthcare providers despite the increasingly individualized nature of treatment.

Sources